Trinity Biotech (TRIB) vs. Its Peers Head to Head Review

Trinity Biotech (NASDAQ: TRIB) is one of 24 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare Trinity Biotech to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Risk & Volatility

How to Become a New Pot Stock Millionaire

Trinity Biotech has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Trinity Biotech’s rivals have a beta of 1.44, indicating that their average share price is 44% more volatile than the S&P 500.

Profitability

This table compares Trinity Biotech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech -40.62% 2.37% 0.99%
Trinity Biotech Competitors -884.88% -64.84% -17.51%

Insider & Institutional Ownership

62.1% of Trinity Biotech shares are owned by institutional investors. Comparatively, 53.6% of shares of all “Diagnostic substances” companies are owned by institutional investors. 12.7% of Trinity Biotech shares are owned by company insiders. Comparatively, 13.5% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Trinity Biotech and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trinity Biotech $99.14 million $2.30 million 19.54
Trinity Biotech Competitors $308.35 million $18.66 million -39.62

Trinity Biotech’s rivals have higher revenue and earnings than Trinity Biotech. Trinity Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Trinity Biotech and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech 0 0 0 0 N/A
Trinity Biotech Competitors 101 367 567 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 15.07%. Given Trinity Biotech’s rivals higher probable upside, analysts clearly believe Trinity Biotech has less favorable growth aspects than its rivals.

Trinity Biotech Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply